Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

PHASE4RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

October 1, 2028

Study Completion Date

October 1, 2030

Conditions
Ovarian Cancer
Interventions
DRUG

Niraparib

Niraparib will be administered orally (PO) daily as tablets at one of three possible dose levels, 100mg/day, 200mg/day or 300mg/day, based upon participant weight, platelet count, and certain drug combinations and conditions assessed at baseline.

Trial Locations (1)

33136

RECRUITING

University of Miami, Miami

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Miami

OTHER